In clinical practice, detecting the loss of KDM5D and UTY could serve as valuable prognostic indicators, aiding in assessing the clinical aggressiveness of bladder cancer and guiding treatment decisions. This evidence concerns the gene KDM5D and urinary bladder cancer.